Dr Gordon Strathdee
Lecturer in Genome Instability
- Email: email@example.com
- Telephone: 0191 282 1349
- Fax: +44 (0) 191 241 8810
- Address: Northern Institute for Cancer Research
Paul O'Gorman Building
Newcastle upon Tyne
The primary interest in my lab is examining the role of a key epigenetic change, altered DNA methylation, in the development, progression and drug sensitivity of leukaemia. This can be split into 3 areas:
The role of DNA methylation in initiation of leukaemia – we are investigating whether alterations in DNA methylation are the initial development in some or all types of leukaemia and whether pre-leukaemic cells with altered DNA methylation are a first step in leukaemia development and whether survival of these pre-leukaemic cells during treatment can lead to relapses in patients.
Identification of novel, leukaemia-cell specific, targets – The optimal type of treatment for cancer would be ones that can specifically target cancer cells, while having little or no impact on normal cells and consequently low toxicity for the patient. We are using a novel bioinformatic approach, combining genome wide DNA methylation and gene expression data to identify genes that are required for the survival of leukaemia cells, but which are not required by normal healthy cells. Targeting the proteins produced by these genes can then give us a way of specifically killing cancer cells that should have little or no impact on healthy cells
Prognostic markers and predictors of drug sensitivity – Leukaemia typically exhibits very large numbers of DNA methylation changes at diagnosis. This gives us a potentially rich source of markers to allow us to predict patient prognosis or response to therapy. We are currently using genome wide DNA methylation data from diagnostic samples and als0o from samples after exposure to therapy to identify methylation based markers that can predict patient outcome and also to identify genes that are playing a direct role in resistance to chemotherapy
Selected Recent Grants
2010 – 2013 Tyneside Leukaemia Research Association, Project grant “Defining the opposing roles of HLXB9 in myeloid and lymphoid leukaemia” Gordon Strathdee, Christine Harrison, Value £85,443
2011 – 2012 Newcastle Healthcare Charity and Newcastle upon Tyne Hospitals NHS Charity, Project Grant “The role of cell type specific age-related DNA methylation in leukaemia development”, Value £9,614
2011 – 2012 Dunhill Medical Trust, Project grant “Investigation of the mechanism of DNA methylation instability and its role in age related disease”, Gordon Strathdee, David Oscier, Mays Jawad, John Mathers, Value £74,357
2011 – 2015 Iraqi Ministry of Education, PhD studentship “Identification and verification of methylation markers for the prediction of outcome in acute lymphoblastic leukaemia” Value £111,000
2014 - 2017 Leukaemia and Lymphoma Research, Project grant “Clinical exploitation of HOXA4 status for directing treatment in CLL patients”. Gordon Strathdee, Elaine Willmore, Value £185,239
2015 – 2016 JGW Patterson Foundation, Project Grant, “Identification of epigenetic regulators of chemosensitivity in chronic lymphocytic leukaemia”.Gordon Strathdee, Elaine Willmore, Value £48,041
Lecturer for BMS2014 Biology of Ageing
Member of steering group for BMS2014 Biology of Ageing
Supervision of undergraduate project students in Biomedical Sciences
Supervision of PhD students
Supervision of Faculty of Medical Sciences MRes and MSci students
- Timms JA, Relton CL, Rankin J, Strathdee G, McKay JA. DNA methylation as a potential mediator of environmental risks in the development of childhood acute lymphoblastic leukaemia. Epigenomics 2016, 8(4), 519-536.
- Barrow TM, Woodhouse L, Junge G, Tudhope SJ, Behardien C, Wallis JP, Marr HJ, Marshall SR, Bown N, Willmore E, Strathdee G. The Role of HOXA4 in Chronic Lymphocytic Leukaemia Progression and Response to Therapy. In: American Society of Hematology (ASH) 58th Annual Meeting & Exposition. 2016, San Diego, CA (USA): American Society of Hematology.
- van Otterdijk SD, Norden J, Dickinson AM, Pearce MS, Relton CL, Mathers JC, Strathdee G. Aberrations in DNA methylation are detectable during remission of acute lymphoblastic leukemia and predict patient outcome. Epigenomics 2015, 7(1), 35-45.
- Smart C, Strathdee G, Watson S, Murgatroyd C, McAllister-Williams RH. Early life trauma, depression and the glucocorticoid receptor gene - an epigenetic perspective. Psychological Medicine 2015, 45(16), 3393-3410.
- Gabriel AS, Lafta FM, Schwalbe EC, Nakjang S, Cockell SJ, Iliasova A, Enshaei A, Schwab C, Rand V, Clifford SC, Kinsey SE, Mitchell CD, Vora A, Harrison CJ, Moorman AV, Strathdee G. Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. Epigenetics 2015, 10(8), 717-726.
- Collerton J, Gautrey HE, van Otterdijk SD, Davies K, Martin-Ruiz C, von Zglinicki T, Kirkwood TBL, Jagger C, Mathers JC, Strathdee G. Acquisition of aberrant DNA methylation is associated with frailty in the very old: findings from the Newcastle 85+Study. Biogerontology 2014, 15(4), 317-328.
- Gautrey HE, van Otterdijk SD, Cordell HJ, Mathers JC, Strathdee G, Newcastle 85 Study Core Team. DNA methylation abnormalities at gene promoters are extensive and variable in the elderly and phenocopy cancer cells. FASEB Journal 2014, 28(7), 3261-3272.
- van Otterdijk SD, Mathers JC, Strathdee G. Do age-related changes in DNA methylation play a role in the development of age-related diseases?. Biochemical Society Transactions 2013, 41(3), 803-807.
- Thathia SH, Ferguson S, Gautrey HE, van Otterdijk SD, Hili M, Rand V, Moorman AV, Meyer S, Brown R, Strathdee G. Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica 2012, 97(3), 371-378.
- Irving L, Mainou-Fowler T, Parker A, Ibbotson RE, Oscier DG, Strathdee G. Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia. Epigenetics 2011, 6(3), 300-306.
- Strathdee G. Methylation markers in the clinical management of leukemia patients – Wave of the future or damp squib?. Epigenomics 2011, 3(4), 391-394.
- Ferguson S, Gautrey HE, Strathdee G. The Dual Role of HLXB9 in Leukemia. Pediatric Blood & Cancer 2011, 56(3), 349-352.
- Strathdee G, Ferguson S, Sim A, Brown R. DNA methylation does not regulate JUNB expression in CML: Comment on "Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia" by Hoshino et al. [Leuk. Res. 33 (2009) 1361-1366]. Leukemia Research 2010, 34(5), 685-686.
- Mathers J, Strathdee G, Relton C. Induction of Epigenetic Alterations by Dietary and Other Environmental Factors. In: Herceg, Z., Ushijima, T, ed. Advances in Genetics: Epigenetics and Cancer, Part B. Amsterdam; London: Academic Press, 2010, pp.4-39.
- Strathdee, G, Sim, A, Soutar, R, Holyoake, TL, Brown, R. HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. Carcinogenesis 2007, 28(2), 299-309.
- Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, Meyer S, Eden T, Dickinson AM, Mountford JC, Jorgensen HG, Soutar R, Brown R. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clinical Cancer Research 2007, 13(17), 5048-5055.
- Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. Journal of Clinical Oncology 2007, 25(29), 4603-4609.
- Lindsey, J. C., Lusher, M. E., Strathdee, G. R., Brown, R., Gilbertson, R. J., Bailey, S., Ellison, D. W., Clifford, S. C. Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. International Journal of Cancer 2006, 118(2), 346-352.
- Strathdee G, Sim A, Parker A, Oscier D, Brown R. Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL. Leukemia 2006, 20(7), 1326-1329.